

RECEIVED  
CENTRAL FAX CENTER

AUG 04 2008

U.S. Patent Application No. 10/549,905  
Docket No.: 13907-02

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Dionysios Papaioannou et al.

U.S. Patent Application No. 10/549,905

Filed: September 20, 2005

For: Polyamine Conjugates With Acidic Retinoids and Preparation Thereof

:  
:  
: Confirmation No.7153  
:  
: Group Art Unit: 1624  
:  
: Examiner: Jarrell, Noble E.

**REQUEST FOR RECONSIDERATION OF THE DECISION ON PETITION UNDER 37 CFR  
1.47(a) (FILING WHEN AN INVENTOR REFUSES TO SIGN) AND RENEWED PETITION  
UNDER 37 CFR 1.47(a)**

**MAIL STOP PETITION**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria VA 22313-1450

Sir:

Pursuant to 37 CFR §1.47(a) and in response to a Decision mailed by the U.S. Patent and Trademark Office on February 4, 2008 ("Decision"), Applicants, Dionysios PAPAIOANNOU, and Dionysios DRAINAS, who executed a Declaration for this Application, respectfully petition to make this application on their own behalf and on behalf of the non-signing joint inventor Prof. Dr. Dionysios TSAMBAOS.

In the Decision it was stated that the Petition under 37 CFR §1.47(a) filed on 20 September 2005 ("September 2005 Petition") was dismissed because, although the September 2005 Petition satisfied most of the requirements of that section, it did not provide the factual proof that the missing joint inventor could not be located or refused to cooperate. Decision, page 2. It was explained that the letter of 2 September 2005 sent by the non-signing inventor indicated affirmative refusal by Prof. Dr. Tsambaos to join in the application, but the letter did not indicate that he had been presented with the application papers.

In a telephone conversation with Mr. James Thomson during the week of July 14, 2008,

U.S. Patent Application No. 10/549,905

Mr. Thomson advised the undersigned counsel that if evidence is submitted that a complete application, including specification, claims, drawings and oath or declaration, is presented to Prof. Dr. Tsambaos, but he refuses to accept delivery of the papers or otherwise indicates his refusal, this would be sufficient proof that Prof. Dr. Tsambaos refused to cooperate. Mr. Thomson explained that silence by Prof. Dr. Tsambaos would be considered an indication of refusal. Applicants appreciate Mr. Thomson's attention to this matter.

Applicants provide herewith a documentary evidence that a complete copy of the subject application (including specification, claims, Abstract and drawings, new Declaration and Assignment) were mailed to the last-known address and e-mailed to the non-signing joint inventor Prof. Dr. Dionysios TSAMBAOS. This Petition is accompanied by:

- (a) a copy of the letter dated July 18, 2008 mailed to the last known address of the inventor Prof. Dr. Dionysios Tsambaos;
- (b) copies of the Declaration executed by the inventors, Dionysios PAPAIOANNOU, and Dionysios DRAINAS, and Application Data Sheet, accompanying the Declaration, both filed in this application on January 17, 2008;
- (c) a copy of the new Declaration included with the July 18, 2008 letter;
- (d) statement by Stanislaus Aksman, Reg. No. 28, 562;
- (e) statement by Arsalan Malik;
- (f) petition for four months extension of time.

Applicants state that the last known address of Prof. Dr. Dionysios TSAMBAOS is:

Prof. Dr. Dionysios Tsambaos  
Clinics of Dermatology  
Medical Sector  
University of Patras  
Patras 26504, Greece

The July 18, 2008 letter stated, in pertinent part, that if we do not receive a reply from

U.S. Patent Application No. 10/549,905


Prof. Dr. Tsambaos by August 1, 2008, we would understand that he refuses to execute the Declaration and participate in the proceedings of this Application. No reply was received from Prof. Dr. Tsambaos. Thus, we conclude that Prof. Dr. Tsambaos refuses to sign the Declaration and join in the Application.

Applicants submit that this renewed Petition, together with the September 2005 Petition, satisfies the requirements of 37 CFR § 1.47(a) and respectfully request reconsideration of the dismissal and the grant of the Petition.

Any questions can be directed to Applicants' undersigned attorney.

The Director is authorized to charge any shortage in fees due in connection with the filing of this paper, including extension of time fees, to Deposit Account 50-2478 and to credit any excess fees to such deposit account.

Respectfully submitted,



Stanislaus Aksman  
Registration No. 28,562

Roberts, Mlotkowski, Safran & Cole P.C.  
Intellectual Property Department  
P.O. Box 10064  
McLean, VA 22102  
Telephone: 703-584-3270  
Facsimile: 703-848-2981  
**August 4, 2008**

RECEIVED  
CENTRAL FAX CENTER

AUG 04 2008



Roberts Mlotkowski Safran &amp; Cole, P.C.

Intellectual Property Law

7918 Jones Branch Drive • Suite 500 • McLean, VA 22102 • Tel: 703.584.3270 • Fax: 703.848.2981 • Email: rmsclaw.com

July 18, 2008

**VIA E-MAIL AND GLOBAL PRIORITY MAIL**

Prof. Dr. Dionysios Tsambaos  
Clinics of Dermatology  
Medical Sector  
University of Patras  
Patras 26504, Greece

Re: U.S. Patent Application No. 10/549,905  
Based on: International Application No. PCT/GR2002/000045  
Title: **Polyamine Conjugates with Acidic Retinoids and Preparation Thereof**  
Our Ref.: 13907.02

Dear Dr. Tsambaos:

We are writing on behalf of our client, Biomedica Life Sciences S.A. (Biomedica). We understand that you have communicated with Biomedica in the past about the above-identified patent application and advised them that you no longer wish to be part of the proceedings in the U.S. Patent and Trademark Office (USPTO) in the above-identified patent application, as set forth in your Declaration dated 5 September, 2005.

Nonetheless, the USPTO rules establish certain requirements in such situations which must be satisfied to establish your refusal to participate in the application.

Accordingly, we enclose the application, including specification, claims, abstract and drawings as filed in the USPTO on 20 September, 2005 and a new Declaration and Assignment documents which need to be executed by each of the inventors and filed in the USPTO in connection with this application.

Please acknowledge safe receipt of all the documents, review, sign the Declaration and Assignment and return them to us at your earliest convenience.


If you refuse to sign the Declaration, please state so in this letter (in the space provided below) and return it to us by fax, e-mail and/or mail by **August 1, 2008**. If you do not reply by that date, we will understand that you refuse to execute the Declaration and refuse to participate in the proceedings of the application in the USPTO.

Prof. Dr. Dionysios Tsambaos  
Department of Dermatology, School of Medicine,  
University of Patras  
July 18, 2008

If you have any questions, please do not hesitate to contact us.

Date:

July 18, 2008

  
Stanislaus Aksman

I refuse to execute the Declaration and refuse to participate in the proceedings of the application in the USPTO.

Date:

\_\_\_\_\_

\_\_\_\_\_  
Prof. Dr. Dionysios Tsambaos

Enclosures

cc: Mr. Yannis Vitsaras  
Ms. Demi Martiadi  
Mr. Alvertos Somarakis

RECEIVED  
CENTRAL FAX CENTER

AUG 04 2008

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN  
APPLICATION DATA SHEET (37 CFR 1.76) AND POWER OF ATTORNEY

Title of Invention Polyamine Conjugates With Acidic Retinoids and Preparation Thereof

As the below named inventor(s), I/we declare that:

This declaration is directed to:

- ☐ The attached application, or  
☒ Application No. 10/549,905, filed on September 20, 2005,  
☐ as amended on \_\_\_\_\_ (if applicable);

I/We believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;

I/We have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;

I/We acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.

All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.

I/We hereby appoint:

Practitioners at Customer Number 25570 as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

## FULL NAME OF INVENTOR(S)

Inventor one: Dionysios PapaioannouSignature: \_\_\_\_\_ Citizen of: GreeceInventor two: Dionysios DrinasSignature: \_\_\_\_\_ Citizen of: GreeceInventor three: Dionysios TsambaosSignature: \_\_\_\_\_ Citizen of: Greece

Inventor four: \_\_\_\_\_

Signature: \_\_\_\_\_ Citizen of: \_\_\_\_\_

APPENDIX A  
RECEIVED  
CENTRAL FAX CENTER

AUG 04 2008

**DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76) AND POWER OF ATTORNEY**

Title of Invention: Polymine Conjugates With Acidic Retinoids and Preparation Thereof

As the below named inventor(s), I/we declare that:

This declaration is directed to:

- ☐ The attached application, or  
☒ Application No. 10/549,905, filed on September 20, 2005,  
☐ as amended on \_\_\_\_\_ (if applicable);

I/We believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;

I/We have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;

I/We acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.

I/We hereby appoint:

Practitioners at Customer Number 25570 as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

**FULL NAME OF INVENTOR(S)**

Inventor one: Dionysios Pappasmanou

Signature: \_\_\_\_\_ Citizen of: Greece

Inventor two: Dionysios Dapinos

Signature: \_\_\_\_\_ Citizen of: Greece

Inventor three: Dionysios Tsambaras

Signature: \_\_\_\_\_ Citizen of: Greece

Inventor four: \_\_\_\_\_

Signature: \_\_\_\_\_ Citizen of: \_\_\_\_\_

## APPENDIX A

Approved through 08/30/2010. OMB 0851-0032  
 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Application Data Sheet 37 CFR 1.76</b>		Attorney Docket Number	13907-02	<b>RECEIVED CENTRAL FAX CENTER AUG 04 2008</b>
		Application Number		
Title of Invention	POLYAMINE CONJUGATES WITH ACIDIC RETINOIDS AND PREPARATION THEREOF			
The application data sheet is part of the provisional or nonprovisional application for which it is being submitted. The following form contains the bibliographic data arranged in a format specified by the United States Patent and Trademark Office as outlined in 37 CFR 1.76. This document may be completed electronically and submitted to the Office in electronic format using the Electronic Filing System (EFS) or the document may be printed and included in a paper filed application.				

## Secrecy Order 37 CFR 5.2

- ☐ Portions or all of the application associated with this Application Data Sheet may fall under a Secrecy Order pursuant to 37 CFR 5.2 (Paper filers only. Applications that fall under Secrecy Order may not be filed electronically.)

## Applicant Information:

<b>Applicant 1</b>				
Applicant Authority <input checked="" type="radio"/> Inventor		<input type="radio"/> Legal Representative under 35 U.S.C. 117		<input type="radio"/> Party of Interest under 35 U.S.C. 118
Prefix	Given Name	Middle Name	Family Name	Suffix
	Dionysios		PAPAIOANNOU	
Residence Information (Select One) <input type="radio"/> US Residency <input checked="" type="radio"/> Non US Residency <input type="radio"/> Active US Military Service				
City	Patras	Country Of Residence	GR	
Citizenship under 37 CFR 1.41(b) i		GR		
Mailing Address of Applicant:				
Address 1		University of Patras		
Address 2		Department of Chemistry		
City	Patras	State/Province		
Postal Code	26504	Country	GR	
<b>Applicant 2</b>				
Applicant Authority <input checked="" type="radio"/> Inventor		<input type="radio"/> Legal Representative under 35 U.S.C. 117		<input type="radio"/> Party of Interest under 35 U.S.C. 118
Prefix	Given Name	Middle Name	Family Name	Suffix
	Dionysios		DRAINAS	
Residence Information (Select One) <input type="radio"/> US Residency <input checked="" type="radio"/> Non US Residency <input type="radio"/> Active US Military Service				
City	Patras	Country Of Residence	GR	
Citizenship under 37 CFR 1.41(b) i		GR		
Mailing Address of Applicant:				
Address 1		University of Patras		
Address 2		School of Medicine, Department of Biochemistry		
City	Patras	State/Province		
Postal Code	26504	Country	GR	
<b>Applicant 3</b>				
Applicant Authority <input checked="" type="radio"/> Inventor		<input type="radio"/> Legal Representative under 35 U.S.C. 117		<input type="radio"/> Party of Interest under 35 U.S.C. 118
Prefix	Given Name	Middle Name	Family Name	Suffix
	Dionysios		TSAMBAOS	
Residence Information (Select One) <input type="radio"/> US Residency <input checked="" type="radio"/> Non US Residency <input type="radio"/> Active US Military Service				
City	Patras	Country Of Residence	GR	

EFS Web 2.2.1



PTO/SB/14 (07-07)

Approved to through 08/30/2010. OMB 0851-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Application Data Sheet 37 CFR 1.76</b>		Attorney Docket Number	13907-02	<b>RECEIVED</b> CENTRAL FAX CENTER JUG 04 2008
		Application Number		
Title of Invention	POLYAMINE CONJUGATES WITH ACIDIC RETINOIDS AND PREPARATION THEREOF			
Citizenship under 37 CFR 1.41(b) i	GR			
<b>Mailing Address of Applicant:</b>				
Address 1	University of Patras			
Address 2	Department of Dermatology, School of Medicine			
City	Rio Patras	State/Province		
Postal Code	26504	Country	GR	
All Inventors Must Be Listed - Additional Inventor Information blocks may be generated within this form by selecting the Add button.				

**Correspondence Information:**

Enter either Customer Number or complete the Correspondence Information section below. For further information see 37 CFR 1.33(a).	
<input type="checkbox"/> An Address is being provided for the correspondence information of this application.	
Customer Number	25570
Email Address	

**Application Information:**

Title of the Invention	POLYAMINE CONJUGATES WITH ACIDIC RETINOIDS AND PREPARATION THEREOF		
Attorney Docket Number	13907-02	Small Entity Status Claimed	<input checked="" type="checkbox"/>
Application Type	Nonprovisional		
Subject Matter	Utility		
Suggested Class (if any)		Sub Class (if any)	
Suggested Technology Center (if any)			
Total Number of Drawing Sheets (if any)	12	Suggested Figure for Publication (if any)	

**Publication Information:**

<input type="checkbox"/> Request Early Publication (Fee required at time of Request 37 CFR 1.219)
<input type="checkbox"/> <b>Request Not to Publish.</b> I hereby request that the attached application not be published under 35 U.S.C. 122(b) and certify that the invention disclosed in the attached application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication at eighteen months after filing.

**Representative Information:**

Representative information should be provided for all practitioners having a power of attorney in the application. Providing this information in the Application Data Sheet does not constitute a power of attorney in the application (see 37 CFR 1.32). Enter either Customer Number or complete the Representative Name section below. If both sections are completed the Customer Number will be used for the Representative Information during processing.			
Please Select One:	<input checked="" type="radio"/> Customer Number	<input type="radio"/> US Patent Practitioner	<input type="radio"/> Limited Recognition (37 CFR 11.9)

Approved for

through 06/30/2010. OMB 0851-0032

PTO/SB/14 (07-07)

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Application Data Sheet 37 CFR 1.76</b>		<b>Attorney Docket Number</b>	13907-02
		<b>Application Number</b>	
<b>Title of Invention</b>	POLYAMINE CONJUGATES WITH ACIDIC RETINOIDS AND PREPARATION THEREOF		
<b>Customer Number</b>	25570		

RECEIVED  
CENTRAL FAX CENTER

AUG 04 2008

**Domestic Benefit/National Stage Information:**

This section allows for the applicant to either claim benefit under 35 U.S.C. 119(e), 120, 121, or 365(c) or indicate National Stage entry from a PCT application. Providing this information in the application data sheet constitutes the specific reference required by 35 U.S.C. 119(e) or 120, and 37 CFR 1.78(a)(2) or CFR 1.78(a)(4), and need not otherwise be made part of the specification.			
<b>Prior Application Status</b>			
<b>Application Number</b>	<b>Continuity Type</b>	<b>Prior Application Number</b>	<b>Filing Date (YYYY-MM-DD)</b>
	a 371 of international	PCT/GR2002/000045	2002-08-22
Additional Domestic Benefit/National Stage Data may be generated within this form by selecting the Add button.			

**Foreign Priority Information:**

This section allows for the applicant to claim benefit of foreign priority and to identify any prior foreign application for which priority is not claimed. Providing this information in the application data sheet constitutes the claim for priority as required by 35 U.S.C. 119(b) and 37 CFR 1.55(a).			
<b>Application Number</b>	<b>Country i</b>	<b>Parent Filing Date (YYYY-MM-DD)</b>	<b>Priority Claimed</b>
			<input type="radio"/> Yes <input type="radio"/> No
Additional Foreign Priority Data may be generated within this form by selecting the Add button.			

**Assignee Information:**

Providing this information in the application data sheet does not substitute for compliance with any requirement of part 3 of Title 37 of the CFR to have an assignment recorded in the Office.				
<b>Assignee 1</b>				
If the Assignee is an Organization check here. <input type="checkbox"/>				
<b>Prefix</b>	<b>Given Name</b>	<b>Middle Name</b>	<b>Family Name</b>	<b>Suffix</b>
<b>Mailing Address Information:</b>				
<b>Address 1</b>				
<b>Address 2</b>				
<b>City</b>		<b>State/Province</b>		
<b>Country i</b>		<b>Postal Code</b>		
<b>Phone Number</b>		<b>Fax Number</b>		
<b>Email Address</b>				
Additional Assignee Data may be generated within this form by selecting the Add button.				

**Signature:**

A signature of the applicant or representative is required in accordance with 37 CFR 1.33 and 10.18. Please see 37 CFR 1.41(d) for the form of the signature.
---


EFS Web 2.2.1

PTO/SB/14 (07-07)

Approved to through 08/30/2010. OMB 0851-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Application Data Sheet 37 CFR 1.76</b>		Attorney Docket Number	13907-02	<b>RECEIVED CENTRAL FAX CENTER AUG 04 2008</b>	
		Application Number			
Title of Invention		POLYAMINE CONJUGATES WITH ACIDIC RETINOIDS AND PREPARATION THEREOF			
Signature			Date (YYYY-MM-DD)	2008-01-17	
First Name	Stanislaus	Last Name	Aksman	Registration Number	28562

This collection of information is required by 37 CFR 1.76. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 23 minutes to complete, including gathering, preparing, and submitting the completed application data sheet form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

RECEIVED  
CENTRAL FAX CENTER

AUG 04 2008

Docket No.: 13907-02

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Dionysios Papaioannou et al.

U.S. Patent Application No. 10/549,905

Filed: September 20, 2005

For: Polyamine Conjugates With Acidic Retinoids and Preparation Thereof

Confirmation No. 7153

Group Art Unit: 1624

Examiner: Jarrell, Noble E.

STATEMENTCommissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:


I, Stanislaus Aksman, state that on July 18, 2008 I sent, or had sent on my behalf, a letter together with the application, including specification, claims, abstract and drawings as filed in the U.S. Patent and Trademark Office (USPTO) on 20 September, 2005 and a new Declaration and Assignment documents via global priority mail and e-mail to the last known address of the inventor Prof. Dr. Dionysios Tsambaos (copies of the Express Mail receipt and USPS Track & Confirm search results and e-mail being attached to the Statement of Mr. Arsalan Malik, enclosed herewith).

I have requested Dr. Tsambaos to acknowledge safe receipt of all the documents, review, sign and return the Declaration and Assignment documents for filing in the U.S. Patent and Trademark Office (USPTO).

Also, I stated in the letter that if Dr. Tsambaos refuses to sign the Declaration, he can state so in the letter and return it to us by fax, e-mail and/or mail by **August 1, 2008**. Otherwise, if no reply is received by that date, we would understand that he refuses to execute the Declaration and refuses to participate in the proceedings of the application in the USPTO.

I have not received a reply from Prof. Dr. Tsambaos.

Respectfully submitted,

  
Stanislaus Aksman  
Registration No. 28,562Roberts Mlotkowski Safran & Cole P.C.  
Intellectual Property Department  
P.O. Box 10064  
McLean, VA 22102  
Telephone: 703-584-3270  
Facsimile: 703-848-2981  
August 4, 2008

RECEIVED 015/020  
CENTRAL FAX CENTER  
AUG 04 2008

Docket No.: 13907-02

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Dionysios Papaioannou et al.

U.S. Patent Application No. 10/549,905

Filed: September 20, 2005

For: Polyamine-Conjugates With Acidic Retinoids and Preparation Thereof

Confirmation No. 7153

Group Art Unit: 1624

Examiner: Jarrell, Noble E.

STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

I, Arsalan Malik, am employed by the law firm of Roberts Mlotkowski Safran & Cole. Mr. Stanislaus Aksman asked me to assist him with mailing to Prof. Dr. Dionysios Tsambaos certain documents for the above-identified matter, i.e., a cover letter signed by Mr. Aksman, and copies of the application, including specification, claims, abstract and drawings, and a Declaration and Assignment, via global priority mail and e-mail. I state that I emailed and mailed such documents to Prof. Dr. Dionysios Tsambaos on July 18, 2008 (copies of the Express Mail receipt and USPS Track & Confirm search results and e-mail being attached).

I have not received a reply from Prof. Dr. Tsambaos.

Respectfully submitted,



Arsalan Malik

Roberts Mlotkowski Safran & Cole P.C.  
Intellectual Property Department  
P.O. Box 10064  
McLean, VA 22102  
Telephone: 703-584-3270  
Facsimile: 703-848-2981  
August 4, 2008

**Arsalan Malik**

---

**From:** Arsalan Malik  
**Sent:** Friday, July 18, 2008 5:38 PM  
**To:** 'tsambaos@med.upatras.gr'  
**Cc:** 'd.martiadi@biomedica.gr'; 'asomarakis@biomedica.gr'; 'vitsaras@biomedica.gr'; Stanislaus Aksman; Iryna Ridchenko  
**Subject:** U.S. Patent Application 10/549,905 - RMSC Ref: 13907.02  
**Attachments:** 1.pdf; 2.pdf; 3.pdf; 4.pdf

Dear Dr. Tsambaos:

Attached please find correspondence from Mr. Stanislaus Aksman dated July 18, 2008, along with several attachments.

Please confirm safe receipt.

If you have any questions or concerns regarding this matter, please feel free to contact our office.

Best regards,

Arsalan Malik  
Assistant to Mr. Stanislaus Aksman

Roberts Mlotkowski Safran & Cole, P.C.  
7918 Jones Branch Drive, Suite 500  
McLean, VA 22102

Direct Dial: (703) 677-3005;  
Main Number: (703) 584-3270; Main Fax: (703) 848-2981

Protected by Attorney-Client Privilege and/or Work Product Exception. This document may contain information that is privileged, confidential and exempt from disclosure under applicable law. If you are not the intended recipient, you are on notice that any unauthorized disclosure, copying, distribution or taking of any action in reliance on the contents of this document is prohibited.

7/18/2008



## Customs Declaration Dispatch Note - CP 72



EC 938 728 137 US

**U.S. POSTAGE PAID  
COMMERCIAL BASE  
PRICING**

<b>From</b> ARSALAN MALIK ROBERTS MLOTKOWSKI SAFRAN & COLE, P.C. 7918 JONES BRANCH DR STE 500 MCLEAN VA 22102-3368 USA		<b>To</b> DR. DIONYSIOS TSAMBAOS CLINICS OF DERMATOLOGY MEDICAL SECTOR UNIVERSITY OF PATRAS 28504 PATRAS GREECE		<b>Scheduled Delivery Date:</b>  	
				<b>Insured Amount (US \$)</b> \$1.00	<b>SDR Value</b> \$0.89
				<b>Importer's Telephone/Fax/Email</b> Phone: 0030 2610 993951	
<b>Detailed description of contents</b>			<b>Qty.</b> 1	<b>Weight lb. oz.</b> 1 0	<b>Value (US \$)</b> 1.00
Legal document					
<b>Contents</b> <input type="checkbox"/> Gift <input checked="" type="checkbox"/> Documents <input type="checkbox"/> Commercial Sample <input type="checkbox"/> Returned Goods <input type="checkbox"/> Other Explanation:			<b>Total Wt.</b> 1 0	<b>Total Value</b> \$1.00	<b>Postage and Fees</b> \$23.88
<b>Comments (e.g., goods subject to quarantine, sanitary/phytosanitary inspection, or other restrictions)</b>			<b>Nonelivery Instructions</b> Return to Sender		<b>Mailing Office Date Stamp</b> 
<b>Sender's Customs Reference (if known)</b>		<b>Importer's Customs Reference - (Fiscal or VAT-number of the addressee, if known)</b>			
<b>License Number(s)</b>	<b>Certificate Number(s)</b>	<b>Invoice Number</b>			
I certify that the particulars given in this customs declaration are correct and that this item does not contain any dangerous articles prohibited by legislation or by postal or customs regulations.					
Sender's signature ARSALAN MALIK		Date 07/18/2008			

PS Form 2976-A-EM

Do not duplicate this form without USPS approval.

The item/parcel may be opened officially.

4 - Sender's Copy

USPS - Track &amp; Confirm

Page 1 of 1

[Home](#) | [Help](#) | [Sign In](#)[Track & Confirm](#)[FAQs](#)

## Track & Confirm

### Search Results

Label/Receipt Number: EC93 8726 137U S  
Status: Out of Foreign Customs

Your item cleared customs in GREECE at 4:44 PM on July 21, 2008.  
Information, if available, is updated every evening. Please check again later.

### Track & Confirm

Enter Label/Receipt Number.

[Go >](#)[Additional Details >](#)[Return to USPS.com Home >](#)

### Notification Options

#### Track & Confirm by email

Get current event information or updates for your item sent to you or others by email. [Go >](#)

#### Proof of Delivery

Verify who signed for your item by email, fax, or mail. [Go >](#)

[Site Map](#)[Contact Us](#)[Forms](#)[Gov't Services](#)[Jobs](#)[Privacy Policy](#)[Terms of Use](#)[National & Premier Accounts](#)

Copyright© 1999-2007 USPS. All Rights Reserved.

No FEAR Act EEO Data FOIA

The Air Mail logo  
This is a registered trademarkRegistered Mail  
This is a registered trademark



USPS - Track &amp; Confirm

Page 1 of 1

[Home](#) | [Help](#) | [Sign In](#)[Track & Confirm](#)[FAQs](#)

## Track & Confirm

### Search Results

Label/Receipt Number: EC93 8726 137U S

Detailed Results:

- Out of Foreign Customs, July 21, 2008, 4:44 pm, GREECE
- Arrived Abroad, July 21, 2008, 4:05 pm, GREECE
- International Dispatch, July 19, 2008, 5:02 pm, JOHN F. KENNEDY APT/NEW YORK
- Processed, July 18, 2008, 5:01 pm, JAMAICA, NY 11499
- Processed, July 18, 2008, 8:19 pm, DULLES, VA 20101
- Acceptance, July 18, 2008, 6:56 pm, MERRIFIELD, VA 22116
- Electronic Shipping Info Received, July 18, 2008

[< Back](#)[Return to USPS.com Home >](#)

### Track & Confirm

Enter Label/Receipt Number.

[Go >](#)

### Notification Options

#### Track & Confirm by email

Get current event information or updates for your item sent to you or others by email.

[Go >](#)

#### Proof of Delivery

Verify who signed for your item by email, fax, or mail.

[Go >](#)[Site Map](#)[Contact Us](#)[Forms](#)[Gov't Services](#)[Jobs](#)[Privacy Policy](#)[Terms of Use](#)[National & Premier Accounts](#)

Copyright© 1999-2007 USPS. All Rights Reserved.

No FEAR Act EEO Data

FOIA

The United States Postal Service  
is a member of the United States Postal ServiceThe United States Postal Service  
is a member of the United States Postal Service